GlassScriptPhysician profile
Brian N Evans
NPI 1932159977
$41,078.60
in general payments reported to CMS, 2019-2025
33 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,935 · 2021: $862 · 2022: $846 · 2023: $1,496 · 2024: $24K · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $5,011 · Food and Beverage: $4,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,100.00 |
| Travel and Lodging | $5,010.74 |
| Food and Beverage | $4,339.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $24,195.38 | 2019-2025 | Novosorb Btm |
| Kerecis Limited | $12,298.69 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Kci USA, INC. | $967.02 | 2019-2023 | Activ.A.C., V.A.C. Dermatac |
| Smith+Nephew, INC. | $819.23 | 2019-2023 | Grafix, Allevyn Gentle Border 10 X 10cm Ctn 10, Acticoat 4" X 4" |
| Aroa Biosurgery Incorporated | $504.18 | 2023-2024 | |
| Sanara Medtech INC. | $305.47 | 2022-2025 | Celleraterx |
| Integra Lifesciences Corporation | $285.15 | 2019-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Next Science LLC | $234.08 | 2021-2023 | Surgx, Blastx, Xperience |
| Acera Surgical, INC. | $173.86 | 2023 | Restrata Wound Matrix |
| Biotissue Holdings INC. | $166.01 | 2021-2022 | |
| Convatec INC. | $156.23 | 2020-2024 | |
| Ets Wound Care LLC | $136.02 | 2024 | Mirragen Advanced Wound Matrix |
| Cardiovascular Systems INC. | $107.55 | 2019 | |
| Melinta Therapeutics, LLC | $107.38 | 2019-2021 | |
| Insmed, INC. | $102.62 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osiris Therapeutics INC. | $58.95 | 2019 | |
| Organogenesis INC. | $58.68 | 2019-2020 | |
| Abbott Laboratories | $42.63 | 2025 | Esprit, Diamondback Peripheral |
| Avita Medical Americas, LLC | $41.58 | 2019 | |
| Misonix INC | $41.11 | 2019-2021 | |
| Medela LLC | $29.13 | 2019 | |
| Solventum Corporation | $27.82 | 2024 | V.A.C.Instill, V.A.C.Ulta, V.A.C. Veraflo |
| Abbvie INC. | $26.93 | 2022 | |
| Innovation Technologies INC | $24.95 | 2021 | |
| Allergan, INC. | $21.69 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.24 | 2023 | Nuzyra |
| Acell, INC. | $21.13 | 2020 | |
| Dutch Ophthalmic, USA | $19.24 | 2020 | |
| Access Pro Medical, LLC | $18.09 | 2025 | Matriderm |
| Tactile Systems Technology INC | $18.08 | 2019 | |
| Celularity INC. | $18.00 | 2019 | |
| Tei Medical INC. | $17.48 | 2019 | |
| Apria Healthcare LLC | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.